228.74  -0.16 (-0.07%)		12-13 16:00
Open: 228.93 High: 228.96 Volume: 19,392,808		Pre. Close: 228.9 Low: 228.74 Market Cap: 43,155(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen maintains an active pipeline of investigational therapies. These encompass TIVDAK for metastatic cervical cancer and other solid malignancies; Ladiratuzumab Vedotin, an ADC aimed at LIV-1 for metastatic breast cancer and other solid tumors; Disitamab Vedotin, a novel ADC specifically targeting HER2; and preclinical candidates such as SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70, intended for diverse oncological conditions. The company has established strategic alliances with several partners, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen, Co. Ltd. Originally incorporated in 1997 as Seattle Genetics, Inc., the firm adopted its current name, Seagen Inc., in October 2020. Its corporate headquarters are located in Bothell, Washington.

Fri, 22 Sep 2023
Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump - Investopedia

Thu, 31 Aug 2023
Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors - Seeking Alpha

Wed, 07 Jun 2023
Profit From The Pfizer Takeover Of Seagen (NASDAQ:SGEN) - Seeking Alpha

Thu, 01 Jun 2023
Seagen shareholders approve $43B acquisition by Pfizer - The Business Journals

Tue, 30 May 2023
Seagen Stockholders Approve Acquisition by Pfizer - Business Wire

Tue, 14 Mar 2023
Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date